Sutton, Andrew J. http://orcid.org/0000-0001-7008-4770
Lupu, Daniel S. http://orcid.org/0000-0001-8174-5482
Bergin, Stephen P. http://orcid.org/0000-0001-5517-9456
Holland, Thomas L. http://orcid.org/0000-0001-7745-9010
McAdams, Staci A.
Dadwal, Sanjeet S. http://orcid.org/0000-0002-1099-0568
Nguyen, Khoi http://orcid.org/0009-0004-3133-4334
Nolte, Frederick S. http://orcid.org/0000-0002-4943-9220
Tremblay, Gabriel http://orcid.org/0000-0001-9001-3128
Perkins, Bradley A. http://orcid.org/0009-0003-4542-2805
Funding for this research was provided by:
Karius, Inc.
Article History
Accepted: 9 June 2024
First Online: 2 July 2024
Declarations
:
: This work was supported by Karius Inc., Redwood City, California, USA. Investigators from Karius were directly involved in design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.
: AJS is an employee of Cytel Inc., Waltham, MA. DSL is an employee of Karius Inc, Redwood City, CA, and may own stock options. SAM is an employee of Karius Inc, Redwood City, CA, and may own stock options. SPB is a consultant to C3J Therapeutics. TLH reports the following: being an advisor and consultant to Aridis, Basilea Pharmaceutica, Karius, and Lysovant; royalties from UpToDate; grants or contracts with Karius (adjudication committee) and with NIH; consulting fees from Pfizer and Affinivax; participation on the Data and Safety Monitoring Board (DSMB) for a platform trial for the <i>Staphylococcus aureus</i> Network Adaptive Platform (SNAP) and for Spero Therapeutics; and being on an advisory board for Basilea. SD reports research grants paid to his institution from Karius, Merck, Gilead, Ansun Biopharma, Allovir, and Geovax. He has served on advisory boards of Merck, Takeda, Allovir, and Aseptiscope, Inc. He is on speaker's bureaus of Merck, Astellas, and Takeda, and reports payment or honoraria from Viracor for an educational event at IDWeek 2022 and from MJH Life Sciences for a cytomegalovirus (CMV) symposium at the American Society of Hematology (ASH) meeting in 2022. He has stock options in Aseptiscope, Inc., Matinas Biopharma, and Cidara Therapeutics. He reports consulting fees from Merck and Allovir; support for attending meetings and/or travel from American Society of Transplantation and Cellular Therapy—Tandem 2022 and 2023 (registration credit), IDWeek 2022—Infectious Diseases Society of America (IDSA) (partial support—airfare), and Immunocompromised Host Society (ICHS) 2022 (airfare and hotel expenses). He reports patent # 9416395, assigned to City of Hope (inventors: Markus Kalkum, Karine Bagramyan, Diana Diaz-Arevalo, James I. Ito, and Sanjeet S. Dadwal), and US Provisional Patent Application no. 63/067,855, assigned to City of Hope (inventors: Markus Kalkum, Daniel Roeth, and Sanjeet S. Dadwal). He reports having a role as Chair of the Transplant Infectious Disease Special Interest Group of American Society of Transplant and Cellular Therapy (ASTCT). FN is an employee of Karius Inc., Redwood City, CA, and may own stock options. BAP is an employee of Karius Inc., Redwood City, CA, has patents planned, issued, or pending with Karius Inc, and may own stock options. All other authors report no potential conflicts.
: No patient-level data were utilized in this analysis.
: BAP conceptualized the study idea. AJS constructed the CEA model, conducted formal analyses, and interpreted the data. KN supported the identification and analysis of secondary data sources. GT provided expert input into the formal analysis. BAP, SPB, TLH, SD, FSN, SAM, and DSL validated the model and its inputs, suggested data sources, and provided expert opinion. AJS and KN participated in drafting the manuscript. All authors reviewed and approved the manuscript before submission.